Immunotherapeutic Strategies for Gastric Carcinoma: A Review of Preclinical and Clinical Recent Development

Abstract EN

Gastric carcinoma (GC) is the 2nd most common cause of cancer-related death.

Despite advances in conventional treatment and surgical interventions, a high percentage of GC patients still have poor survival.

Recently, immunotherapy has become a promising approach to treat GC.

Here, we present preclinical and clinical studies encouraging the use of vaccination, adoptive T-cell therapy (ACT), and immune checkpoint inhibitors, such as programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4).

The ongoing immunotherapy clinical trials have shown promising results in safety and tolerability even in late-stage GC patients.

Moreover, we highlight that the combination of ACT with chemotherapy could be the best choice to treat GC.